Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yu Nakatani"'
Autor:
Michimi Otani, MD, Miki Nishimori, MD, PhD, Hitomi Iwasa, MD, PhD, Mamiko Iwamura, MD, Takayasu Izumi, MD, Kosuke Nakaji, MD, Noriko Nitta, MD, Kana Miyatake, MD, Rika Yoshimatsu, MD, PhD, Tomoaki Yamanishi, MD, Tomohiro Matsumoto, MD, PhD, Yasushi Osaki, MD, PhD, Noriko Wada, MD, Makoto Toi, MD, PhD, Marino Yamamoto, MD, PhD, Yu Nakatani, MD, Tetsuya Kubota, MD, PhD, Takuji Yamagami, MD, PhD
Publikováno v:
Radiology Case Reports, Vol 18, Iss 11, Pp 4036-4041 (2023)
Spontaneous regression (SR) of cancer is very rare, especially of small cell lung cancer (SCLC). Recently, an association of paraneoplastic neurological syndrome (PNS) has been reported as a cause of SR of cancer, and onconeural antibodies are a poss
Externí odkaz:
https://doaj.org/article/80d058a6c1d146a4bcb68363eb6bea49
Autor:
Tsukie Kin Tsukuda, Hiroshi Ohnishi, Minoru Fujimoto, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka, Akihito Yokoyama
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Progressive fibrosing interstitial lung diseases (PF-ILDs) have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the det
Externí odkaz:
https://doaj.org/article/c29e9a66f1ee48548423727a2267ec30
Autor:
YU NAKATANI, TETSUYA KUBOTA, YOSHIAKI HIRAKAWA, TAKASHI ANAYAMA, TOMOKI KIMURA, AKIHITO YOKOYAMA
Publikováno v:
In Vivo; May/Jun2024, Vol. 38 Issue 3, p1483-1488, 6p
Autor:
Shingo MASUDA, Yu NAKATANI, Yusuke OTSUKA, Hideki MORI, Hirokazu GOSHO, Jun YASUDA, Shinya ODA, Daisuke YAMAKAWA, Syota YAMAGUCHI
Publikováno v:
Kansenshogaku Zasshi. 97:26-31
Publikováno v:
American journal of respiratory and critical care medicine.
Autor:
Tsukie Kin, Tsukuda, Hiroshi, Ohnishi, Minoru, Fujimoto, Yu, Nakatani, Kazufumi, Takamatsu, Tetsuji, Naka, Akihito, Yokoyama
Publikováno v:
Scientific reports. 12(1)
Progressive fibrosing interstitial lung diseases (PF-ILDs) have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the deterioratio
Autor:
Tsukie Kin Tsukuda, Minoru Fujimoto, Hiroshi Ohnishi, Yu Nakatani, Kazufumi Takamatsu, Tetsuji Naka, Akihito Yokoyama
Background:Progressive fibrosing interstitial lung diseases have a poor prognosis and may be resistant to corticosteroids and/or immunosuppressants, but antifibrotic therapies such as nintedanib and pirfenidone have been shown to slow the deteriorati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a71269f7d93888c476e0e2fbabb038d5
https://doi.org/10.21203/rs.3.rs-1271280/v1
https://doi.org/10.21203/rs.3.rs-1271280/v1
Publikováno v:
Internal Medicine
Publikováno v:
American Journal of Respiratory & Critical Care Medicine; 4/15/2023, Vol. 207 Issue 8, p1092-1094, 3p
Autor:
Hiroyuki Uchino, Kusuki Nishioka, Kenya Nishioka, Yu Nakatani, Daisuke Hasegawa, Ko-ichi Kawahara, Naomi Hara, Eskil Elmér, Naoko Yagishita, Hiroko Kokuba, Fukami Nakajima, Tomoko Saito-Fujita, Satoko Aratani, Toshihiro Nakajima, Tomoo Sato, Saori Morota, Magnus Hansson, Itsuro Higuchi, Katsuko Sudo, Eiichi Sato, Hidetoshi Fujita, Masahiko Usui, Natsumi Araya, Chie Usui, Yoshihisa Yamano, Masato Inazu, Ikuro Maruyama
Publikováno v:
The EMBO Journal. 34:1042-1055
Obesity is a major global public health problem, and understanding its pathogenesis is critical for identifying a cure. In this study, a gene knockout strategy was used in post-neonatal mice to delete synoviolin (Syvn)1/Hrd1/Der3, an ER-resident E3 u